Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-11-2008 | Article

Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers

Authors: M. Eisenblätter, C. Klaus, M. W. R. Pletz, H. Orawa, H. Hahn, J. Wagner, H. Lode

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2008

Abstract

Oral viridans streptococci are a reservoir of resistance genes for pathogens. Through prolonged exposure, long-acting macrolides (e.g., azithromycin) may induce the resistance of the commensals to macrolides more frequently than macrolides with a shorter half-life (e.g., clarithromycin). In a prospective, randomized, evaluator-blinded trial in healthy volunteers receiving standard courses of either azithromycin (n = 20) or clarithromycin (n = 20), we compared the susceptibility of oral viridans streptococci to macrolides over a period of 12 weeks. There was a significant temporal increase in the numbers of resistant isolates in both groups (p < 0.0005 at week 1). The proportion of macrolide-resistant isolates over time was significantly higher following azithromycin treatment (p = 0.0005), but returned to baseline values until week 12 in both groups. Temporal differential effects of azithromycin and clarithromycin on the induction of resistance were observed and need to be investigated regarding their effect on co-colonizing pathogens.

Bennett J, St Geme JW 3rd (1999) Bacterial resistance and antibiotic use in the emergency department. Pediatr Clin North Am 46:1125–1143PubMedCrossRef

Cantón R, Unal S, Farrell DJ (2007) Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004). Int J Antimicrob Agents 30:546–550PubMedCrossRef

Arvand M, Hoeck M, Hahn H et al (2000) Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin. J Antimicrob Chemother 46:621–624PubMedCrossRef

Brandt CM, Honscha M, Truong ND et al (2001) Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb Drug Resist 7:165–170PubMedCrossRef

Bergman M, Huikko S, Pihlajamäki M et al (2004) Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin Infect Dis 38:1251–1256PubMedCrossRef

Schoening TE, Wagner J, Arvand M (2005) Prevalence of erythromycin and clindamycin resistance among Streptococcus agalactiae isolates in Germany. Clin Microbiol Infect 11:579–582PubMedCrossRef

Cha S, Lee H, Lee K et al (2001) The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea. J Infect Chemother 7:81–86PubMedCrossRef

Cizman M, Pokorn M, Seme K et al (2001) The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J Antimicrob Chemother 47:475–477PubMedCrossRef

Seppälä H, Klaukka T, Vuopio-Varkila J et al (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 337:441–446PubMedCrossRef

10.

Doern GV, Brown SD (2004) Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–01. J Infect 48:56–65PubMedCrossRef

11.

Teng LJ, Hsueh PR, Chen YC et al (1998) Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother 41:621–627PubMedCrossRef

12.

Ioannidou S, Tassios PT, Kotsovili-Tseleni A et al (2001) Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. Int J Antimicrob Agents 17:195–201PubMedCrossRef

13.

Aracil B, Miñambres M, Oteo J et al (2001) High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J Antimicrob Chemother 48:592–594PubMedCrossRef

14.

Seppälä H, Haanperä M, Al-Juhaish M et al (2003) Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 52:636–644PubMedCrossRef

15.

Luna VA, Coates P, Eady EA et al (1999) A variety of gram-positive bacteria carry mobile mef genes. J Antimicrob Chemother 44:19–25PubMedCrossRef

16.

Villedieu A, Diaz-Torres ML, Roberts AP et al (2004) Genetic basis of erythromycin resistance in oral bacteria. Antimicrob Agents Chemother 48:2298–2301PubMedCrossRef

17.

Cerdá Zolezzi P, Laplana LM, Calvo CR et al (2004) Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 48:3462–3467PubMedCrossRef

18.

Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52:11–17PubMedCrossRef

19.

Granizo JJ, Aguilar L, Casal J et al (2000) Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997). J Antimicrob Chemother 46:959–964PubMedCrossRef

20.

Reinert RR, Al-Lahham A, Lemperle M et al (2002) Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 49:61–68PubMedCrossRef

21.

Fuchs PC, Barry AL, Brown SD (2001) Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin. J Clin Microbiol 39:43–46PubMedCrossRef

22.

Malhotra-Kumar S, Lammens C, Coenen S et al (2007) Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369:482–490PubMedCrossRef

23.

Kastner U, Guggenbichler JP (2001) Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 29:251–256PubMedCrossRef

24.

Mazzariol A, Koncan R, Vitali LA et al (2007) Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother 59:1171–1176PubMedCrossRef

25.

Patel KB, Xuan D, Tessier PR et al (1996) Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40:2375–2379PubMed

26.

Noreddin AM, Roberts D, Nichol K et al (2002) Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 46:4029–4034PubMedCrossRef

27.

Zhanel GG, DeCorby M, Noreddin A et al (2003) Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52:83–88PubMedCrossRef

28.

Clewell DB, Flannagan SE, Jaworski DD (1995) Unconstrained bacterial promiscuity: the Tn916–Tn1545 family of conjugative transposons. Trends Microbiol 3:229–236PubMedCrossRef

29.

Felmingham D, Reinert RR, Hirakata Y et al (2002) Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 50(Suppl S1):25–37PubMed

Title: Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers
Authors: M. Eisenblätter
C. Klaus
M. W. R. Pletz
H. Orawa
H. Hahn
J. Wagner
H. Lode
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-008-0547-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2008

A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia

Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients

Divergence within the marker region of the groESL operon in Anaplasma phagocytophilum

A retrospective study of 230 consecutive patients hospitalized for presumed travel-related illness (2000–2006)

Involvement of the Helicobacter pylori plasticity region and cag pathogenicity island genes in the development of gastroduodenal diseases

Campylobacter species isolated from extra-oro-intestinal abscesses: a report of four cases and literature review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials